Merck Releases Keytruda Data In Frontline Endometrial Cancer Patients


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


  • Merck & Co Inc (NYSE:MRKannounced results from the Phase 3 NRG‑GY018 trial of Keytruda (pembrolizumab) combined with standard-of-care chemotherapy (carboplatin and paclitaxel), then continued as a single agent every six weeks for up to 14 cycles for the first-line treatment of stage III-IV or recurrent endometrial carcinoma whose cancer was either mismatch repair proficient (pMMR) or mismatch repair deficient (dMMR). 
  • Keytruda, in combination with chemotherapy, reduced the risk of disease progression or death by 46% compared to just chemotherapy. The primary endpoint, median progression-free survival, was 13.1 months compared to 8.7 months in patients taking just chemotherapy.
  • Related: Merck's Keytruda Combo Therapy Less Effective Than Chemo In Lung Cancer Patients, Data Shows.
  • In the mismatch repair deficient (dMMR) group of 225 patients, the risk of disease progression or death was reduced by 70% compared to just chemotherapy. The median progression-free survival wasn't reached compared to 7.6 months with chemo alone.
  • The company said no new safety signals were found. Still, in the pMMR group, grade 3 to 5 adverse events occurred in 55.1% of patients receiving Keytruda compared to 45.3% of patients receiving chemotherapy alone.
  • In the dMMR group, grade 3 to 5 adverse events occurred in 63.3% of patients receiving the Keytruda plus chemo combo compared to 47.2% of patients taking just chemotherapy. 
  • Merck noted that no adverse events resulted in death in either cohort.
  • Price Action: MRK shares are down 0.50% at $106.40 on the last check Tuesday.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs